Human chorionic gonadotropin (HCG) is a glycoprotein hormone that mimics luteinizing hormone (LH). It is used clinically for fertility and hypogonadism and off-label to maintain testicular function during testosterone replacement therapy.
HCG binds to LH receptors on Leydig cells in the testes, stimulating endogenous testosterone and intratesticular steroidogenesis. In women, it triggers ovulation by mimicking the LH surge.
Commonly reported research ranges: 250–1,500 IU per injection (roughly 28–167 mcg), typically 2–3x weekly.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
A widely used reconstitution for a 1 mg vial is 2 ml of bacteriostatic water. With a typical 56 mcg dose this works out to the unit count shown in the calculator below.
Biphasic: initial ~6 hours, terminal ~36 hours.
This half-life informs how often HCG is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Lyophilized refrigerated. Reconstituted: refrigerated 2–8 °C, use within 30 days.
FDA approved for hypogonadism, cryptorchidism, and fertility indications. Off-label use for TRT-support is common but not FDA approved.
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Human chorionic gonadotropin (HCG) is a glycoprotein hormone that mimics luteinizing hormone (LH). It is used clinically for fertility and hypogonadism and off-label to maintain testicular function during testosterone replacement therapy.
HCG binds to LH receptors on Leydig cells in the testes, stimulating endogenous testosterone and intratesticular steroidogenesis. In women, it triggers ovulation by mimicking the LH surge.
Commonly reported ranges are 250–1,500 IU per injection (roughly 28–167 mcg), typically 2–3x weekly. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
Biphasic: initial ~6 hours, terminal ~36 hours. This influences how often it is administered.
A common approach is to add 2 ml of bacteriostatic water to a 1 mg vial. Use the reconstitution calculator for exact unit counts.
Gynecomastia (estrogen conversion); Acne; Water retention; Mood changes; Injection-site reactions; Rare: ovarian hyperstimulation syndrome in women.
FDA approved for hypogonadism, cryptorchidism, and fertility indications. Off-label use for TRT-support is common but not FDA approved.
Registered or published clinical-trial sources for HCG are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.